On January 6, 2020 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "the Company") reported the status of acquisition of its own shares as stated below (Press release, Astellas, JAN 6, 2020, View Source [SID1234552693]). The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Particulars

1. Class of shares acquired: Common stock of the Company

2 Total number of shares acquired: 7,360,600 shares

3 Total amount of acquisition cost: 13,738,364,050 yen

4 Period of acquisition: From December 1, 2019 to December 23, 2019

5 Method of acquisition: Purchased on the Tokyo Stock Exchange

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on October 31, 2019)
-Class of shares to be acquired: Common stock of the Company

-Total number of shares to be acquired: Up to 32 million shares (Ratio to the total number of shares outstanding [excluding treasury stock]: 1.70%)

-Total amount of acquisition cost: Up to 50 billion yen

-Period of acquisition: From November 1, 2019 to January 31, 2020

2. Accumulated Company’s own shares acquired through December 31, 2019, pursuant to the above board resolution

-Total number of shares acquired: 20,026,200 shares

-Total amount of acquisition cost: 36,866,306,500 yen

On January 3, 2020 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, president and chief executive officer, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2020, at 4:00 p.m. (PST) followed by a Q&A session at 4:30 p.m. (PST) (Press release, Thermo Fisher Scientific, JAN 3, 2020, View Source [SID1234552692]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the webcast of the presentation and the Q&A session via the Investors section of our website, www.thermofisher.com.

On January 3, 2020 Accelerate Diagnostics, Inc. (NASDAQ: AXDX) reported that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2020, at 11:30 a.m. Pacific Time (Press release, ACCELERATED MEDICAL DIAGNOSTICS, JAN 3, 2020, View Source [SID1234552690]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be accessible through the company’s investor relations website at ir.axdx.com. A replay of the webcast will be available for at least 30 days following the conference.

On January 3, 2020 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reported that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 6:00 p.m. ET, followed by a question and answer session at 6:30 p.m. ET (Press release, BD Pharmaceutical Systems, JAN 3, 2020, View Source [SID1234552689]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live webcasts of BD’s presentations can be accessed from the BD corporate website at www.bd.com/investors and will be available for replay through Tuesday, January 21, 2020.

On January 3, 2020 McKesson Corporation (NYSE:MCK) reported that its third quarter fiscal 2020 financial results will be released before market open on Tuesday, February 4, 2020 (Press release, McKesson, JAN 3, 2020, View Source [SID1234552688]). The company will host a conference call at 8:00 AM Eastern Time to discuss the financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the conference call will be available on McKesson’s Investor Relations website at View Source, along with the company’s earnings press release, financial tables and slide presentation. The conference call can also be accessed by dialing 786-815-8297. The password is ‘McKesson’.